Evaluation of Dry Eyes
Defines Molina Healthcare coverage positions for diagnostic tear-film tests in individuals suspected of having dry eye disease, including covered indications for tear osmolarity and non-covered tests (MMP-9, lactoferrin, IgE, and other tests). Also lists relevant terminology, background, guidelines, FDA approvals, and applicable procedure codes.
Revision Date noted 07/01/2025 (policy retained coverage stance: tear osmolarity meets coverage; MMP-9, lactoferrin, IgE, and other tests do not).
07/01/2025: Reviewed and updated background, guidelines and recommendations, and evidence-based scientific references.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.